{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"65"}]}],"title":"Hemoglobin, Any Increase, n=123, 239"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"11"}]}],"title":"Hemoglobin, Increase to Grade 3, n=123, 239"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"}]}],"title":"Hemoglobin, Increase to Grade 4, n=123, 239"},{"categories":[{"measurements":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"102"}]}],"title":"Lymphocytes, Any Increase, n=123, 238"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"23"}]}],"title":"Lymphocytes, Increase to Grade 3, n=123, 238"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}],"title":"Lymphocytes, Increase to Grade 4, n=123, 238"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"79"}]}],"title":"Neutrophils, Any Increase, n=123, 239"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"10"}]}],"title":"Neutrophils, Increase to Grade 3, n=123, 239"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Neutrophils, Increase to Grade 4, n=123, 239"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"86"}]}],"title":"Platelets, Any Increase, n=123, 239"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"7"}]}],"title":"Platelets, Increase to Grade 3, n=123, 239"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"title":"Platelets, Increase to Grade 4, n=123, 239"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"106"}]}],"title":"White Blood Cells, Any Increase, n=123, 239"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}]}],"title":"White Blood Cells, Increase to Grade 3, n=123, 239"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"White Blood Cells, Increase to Grade , n=123, 239"}],"denoms":[{"counts":[{"groupId":"OG000","value":"123"},{"groupId":"OG001","value":"239"}],"units":"Participants"}],"description":"Shifts in hematology values by grade were summarized based on the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE Version 3.0). Grade refers to the severity of the AE. The CTCAE Version 3.0 displays Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline. Participants with a missing baseline grade were assumed to have a baseline Grade of 0. Any increase in grade from baseline and shifts to Grade 3 (severe AE) and 4 (life-threatening or disabling AE) at any point in the study after baseline are reported.","groups":[{"description":"Matching placebo tablets administered orally once daily for a duration until participants experienced disease progression, death, unacceptable toxicity, or participants withdrew consent","id":"OG000","title":"Placebo"},{"description":"Pazopanib 200 milligrams (mg) and 400 mg film-coated tablets (containing pazopanib monohydrochloride) administered orally at a dose of 800 mg once daily for a duration until participants experienced disease progression, death, unacceptable toxicity, or participants withdrew consent","id":"OG001","title":"Pazopanib"}],"paramType":"NUMBER","populationDescription":"Safety Population. Data were analyzed for participants who were on-therapy and provided data at the indicated time point.","reportingStatus":"POSTED","timeFrame":"From baseline (Day 1) until study drug discontinuation or end of treatment (assessed for an average of 20 weeks)","title":"Number of Participants With the Indicated Grade Shifts From Baseline Grade for Hemoglobin Level, Lymphocyte Count, White Blood Cell Count, Neutrophil Count, and Platelet Count","type":"SECONDARY","unitOfMeasure":"participants"}